Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia
Summary
The main goal of this study is to assess the safety and tolerability of RAD001 in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy. The secondary goals are to investigate the likely causes of drug response or failure.
Study Design
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Conditions
Acute Myeloid Leukemia
Intervention
RAD001(Everolimus)
Location
BaysideHealth, The Alfred Hospital
Melbourne
Victoria
Australia
3004
Status
Recruiting
Source
Bayside Health
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00636922
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
Leukemia, Myelomonocytic, Acute
A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. At least 20% of non-erythroid cells are of monocytic origin.
Leukemia, Eosinophilic, Acute
A rare acute myeloid leukemia characterized by abnormal EOSINOPHILS in the bone marrow.
Leukemia, Promyelocytic, Acute
An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.
Leukemia, Biphenotypic, Acute
An acute leukemia exhibiting cell features characteristic of both the myeloid and lymphoid lineages and probably arising from MULTIPOTENT STEM CELLS.
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Clinical Trials
Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia
This is a nonrandomized, open-label study to evaluate the efficacy and safety of combination treatment of Nilotinib and RAD001 in the treatment of c-kit + AML. Patients refractory to stand...
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
The goal of Phase I of this clinical research study is to find the highest tolerable dose of RAD001 (everolimus) when given in combination with the standard chemotherapy regimens to patien...
Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
The purpose of this research study is to determine the safety of RAD001(Everolimus) and the highest dose of this drug that can be given to people safely. RAD001(Everolimus) is a drug that...
RATIONALE: Drugs used in chemotherapy, such as mitoxantrone hydrochloride, cytarabine, etoposide, and idarubicin, work in different ways to stop the growth of cancer cells, either by killi...
Diagnostic Study of Gene Alterations in Patients With Acute Myeloid Leukemia
RATIONALE: Diagnostic procedures, such as genetic testing, may improve the ability to detect acute myeloid leukemia and determine the extent of disease. PURPOSE: Diagnostic study to try t...
PubMed Articles
The role of peptide and DNA vaccines in myeloid leukemia immunotherapy.
ABSTRACT: While chemotherapy and targeted therapy are successful in inducing the remission of myeloid leukemia as acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), the disease remains l...
Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse.
BackgroundAlthough patients with acute myeloid leukemia who were treated with conventional chemotherapy still have a substantial risk of relapse, the prognostic factors and optimal treatments after re...
Our knowledge about acute promyelocytic leukemia (APL) patients is mainly based on data from clinical trials, whereas population-based information is scarce. We studied APL patients diagnosed between...
